MARKET

BRNS

BRNS

Barinthus Biotherapeutics plc
NASDAQ
0.7001
+0.0190
+2.79%
Closed 16:00 12/31 EST
OPEN
0.6680
PREV CLOSE
0.6811
HIGH
0.7360
LOW
0.6680
VOLUME
113.61K
TURNOVER
--
52 WEEK HIGH
2.920
52 WEEK LOW
0.6400
MARKET CAP
28.59M
P/E (TTM)
-0.3721
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BRNS last week (1222-1226)?
Weekly Report · 12/29/2025 10:06
Weekly Report: what happened at BRNS last week (1215-1219)?
Weekly Report · 12/22/2025 10:06
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 12/15/2025 17:00
Weekly Report: what happened at BRNS last week (1208-1212)?
Weekly Report · 12/15/2025 10:12
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
TipRanks · 12/11/2025 11:16
Barinthus Biotherapeutics Updates on AVALON Trial Progress
TipRanks · 12/10/2025 13:28
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
TipRanks · 12/10/2025 13:16
Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
Benzinga · 12/10/2025 13:01
More
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Webull offers Barinthus Biotherapeutics PLC - ADR stock information, including NASDAQ: BRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRNS stock methods without spending real money on the virtual paper trading platform.